between phases for 1 and in P2 for another. See if they can get anything moving interest wise. I see some decent potential though I didn't expect my patience to be tested this much. How about 6 - 9 months then this starts building for phase 3 kick off for arhalofenate and by the end of the year for MBX-8025 data. Partnership I think will happen with at least one likely candidate being J&J. For now, no one seems to be in a hurry to accumulate so it's a coin toss until something solid comes up. Need to confirm a bottom, then reversal. No target till then. I'll probably be in accumulation mode for a while. I did cut this loose from my IRA but will continue to accumulate in my regular account.
MBX-8025 - Johnson & Johnson Pharmaceutical Research & Development filed an IND for this compound with the FDA in July 2005 and subsequently transferred the application to CymaBay in March 2007.
News 
Market Data 
Discover 
